Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354968 | 1.00 | NPC1 (0.71) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL30485791 | 0.91 | NPC1 (0.80) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL22232687 | 0.91 | NPC1 (0.80) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL25431226 | 0.86 | RAB9A (0.76) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL29151219 | 0.86 | NPC1 (0.72) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL12700208 | 0.85 | GAA (0.59) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL5016607 | 0.84 | ALDH1A1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL30354766 | 0.84 | RAB9A (0.65) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL30354939 | 0.84 | RAB9A (0.65) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL29151264 | 0.84 | RAB9A (0.65) | NPC1MAPTRAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278965-A1 | NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-07 | — | — | US | disclosed |
| EP-4169916-A1 | CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021256902-A1 | CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF | 한국과학기술연구원 | 2021-12-23 | — | — | WO | disclosed |
| EP-3362436-B1 | PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS | UNIV ANTWERPEN (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278965-A1 | NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | AADAC, CBR3, MTCL3 | NPC1 2328/4885MAPT 2830/4885RAB9A 1162/4885 |
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | NPC1 1139/4885MAPT 4022/4885RAB9A 3175/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | NPC1 1139/4885MAPT 4022/4885RAB9A 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.